Aduro BioTech

Clinical Trial Tests Drug Combination in Mesothelioma

UPDATE: Aduro Biotech announced on December 12 that they have decided to discontinue its CRS-207 clinical trial and wind down each of its trials in mesothelioma. This decision was made based on preliminary results from the trials, as well as a business and commercial assessment.
On November 8, 2017, the Meso Foundation hosted a Meet the Mesothelioma […]


Pharmaceutical Company Completes Enrollment for Phase 1B Trial for Mesothelioma

If you attended our International Symposium on Malignant Mesothelioma in March of this year, you may recall the buzz of excitement that coursed throughout the scientific sessions. This buzz sparked excitement throughout the entire mesothelioma community, as we discussed advances in science, the needs of those affected by this disease, and the work being done […]


Updates from ASCO: CRS-207 Vaccine Study Results

Aduro BioTech is conducting a clinical trial to test an investigational new immunotherapy for malignant pleural mesothelioma (MPM). This therapy, called CRS-207, is given to a patient in combination with chemotherapy in hopes of encouraging the body’s normal defense mechanisms to fight off the cancer. This trial aims to enroll up to 60 patients at […]


Meet the Mesothelioma Experts: Stephen Isaacs Discusses New Clinical Trial Using Listeria Bacteria

On September 10, the Meso Foundation will interview Stephen Isaacs, the chairperson, president, and CEO of Adura BioTech, during a new installment of the Foundation’s Meet the Mesothelioma Experts live broadcast. The interview will be led by the Meso Foundation’s executive director and mesothelioma expert nurse practitioner, Mary Hesdorffer, APRN.
The focus of the interview will […]